Skip to main content


Pharmacologic Efficacy in Still's Disease

A systematic review of the effectiveness and safety of pharmacological treatments for adult-onset Still’s disease (AOSD) supports the use of either IL-1 or IL-6 inhibitors.

A metanalysis was performed using databases, trial

Read Article
Is IL-6 a potential therapeutic target in neuropsychiatric lupus (NPSLE)? Just published in the Journal of Neuroinflammation- Some interesting findings from the Putterman lab in a murine NPSLE model...

chaim putterman @ChaimPutterman( View Tweet )

Window of Opportunity in Psoriatic Arthritis

A Dutch Early Psoriatic Arthritis cohort study shows that psoriatic arthritis (PsA) patients treated early (referred and diagnosed  within in less than 12 weeks) had the best clinical outcomes. 

Read Article

Naysayers & Disrupters (3.22.2024)

Dr. Jack Cush reviews the news and journal reports from the past week - including a few contrary reports on infection, seropositivity and plasmapheresis.

Read Article

Ides of March (3.15.2024)

Dr. Jack Cush has advice for Caesar and the superstitious, and covers pregnancy, platelets, dialysis and vaccinations in Lupus.

  1. Dutch study of 586 RA pts on bDMARDs found more nonserious infections (NSIE) (77/100PYs) than serious infx (SIE)(1.3/100Pys). Upper respiratory

Read Article

US Trends in RA DMARD Use 2017-2021

A trend analysis of DMARDs shows that only half of rheumatoid arthritis (RA) patients are taking DMARDs, and that the COVID-19 pandemic substantially affected DMARD use. Despite numerous DMARD advances and evolving treatment guidelines since 1990, older therapies are still commonly used and

Read Article

JAMA Review of DMARD Use in Rheumatoid Arthritis

JAMA has reviewed the "2022 EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs". 

Read Article

Effective Treatments for Still's Disease

A systematic review of pharmacological treatments for adult-onset Still disease (AOSD) supports the efficacy of tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK).

Data and results from 44 studies abstracts evaluated treatments, including nonsteroidal antiinflammatory drugs (

Read Article

Depression and RA (3.8.2024)

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week.

Read Article

Sniffles & Arthritis (3.1.2024)

Dr. Jack Cush reviews the news and journal reports from the past week on Are these associations with infection, biomarkers and weather real or imaginary? Linked or luck? Causal or casual?  You decide....

  1. No clear link between weather & MSK symptoms

Read Article

Cochrane Review: How Good is Ultrasound Diagnosing GCA?

Is temporal artery ultrasound equivalent or superior to the reference standard of temporal artery biopsy when diagnosing giant cell arteritis (GCA)?

Read Article
Dr. J. Giles reviews adipose tissue as a source of inflammatory cytokines like TNF, IL-6, IL-1, IL17, etc. #RWCS24 @RWCSmtg @RheumNow
Dr. Rachel Tate @uptoTate( View Tweet )

VITAL Info on Autoimmune Disease (2.9.2024)

Dr. Jack Cush reviews the journal reports from the past week on Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".

  1. Many #RA pts remain on Steroids despite b/tsDMARD use! Study 228 #RA pts

Read Article

Pre-Treatment Testing with Biologics Falls Short

US commercial insurance claim analysis of laboratory screening and monitoring practices in chronic inflammatory skin disease (CISD) patients shows that < 60% received the recommended pretreatment testing when starting systemic immunomodulatory treatment.

Read Article
Interesting nuance from @philseo re tocilizumab in GCA. For new onset disease, it may be appropriate to use every other week tocilizumab @RheumNow #RNL2024
Richard Conway @RichardPAConway( View Tweet )

Best Treatments for COVID-Related MIS-C

The RECOVERY trial focused on pediatric MIS-C patients treated with immunomodulators and anti-cytokine therapy demonstrated the benefits of first-line therapy with intravenous methylprednisolone or second-line tocilizumab in children refractory to initial treatment. Neither IV

Read Article
Real-world data of 5070 RA pts (1816 Rx w/ b/tsDMARDs) showed the use of tsDMARD considerably increased from 2012 to 2021. All b/tsDMARDs pts improved Dz activity & function/ 10 yr effiicacy best for IL6Ri in switch pts and ABA in bNAIVE pts
Dr. John Cush @RheumNow( View Tweet )

2023 Rheumatology Year in Review

Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.  

2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.  

Read Article

2023 Rheumatology Year in Review

Here is my top 10 list (in no particular order) of 2023 advances, game-changers, and developments that changed, or will soon change, rheumatologic practices.

Read Article

StillsNow Podcast December 2023 - ACR23 Highlights

Dr. Jack Cush reviews selected AOSD & systemic JIA abstracts from the ACR 2023 Annual meeting held in San Diego, November 12th thru 16th.

  1. Abstract 0761. EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and

Read Article

Best of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome

A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance and expert opinion on the evaluation, management and monitoring of patients with Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with the primary

Read Article
UK Dermatology Registry of 13 699 Psoriasis pts on biologics (25K biologic exposures) found 1% risk of paradoxical eczema. Biologics included inhibitors of TNF, IL-17, IL12/23, IL-23. Lowest risk w/ IL-23i (0.56/100kPY), and higher w/ IL-17i (1.22)
Dr. John Cush @RheumNow( View Tweet )

When should we be starting therapy in GCA and PMR?

The problem with having therapies that work is that you then have to figure out what to do with them. You cannot hide behind a shrug of the shoulders, or the ambiguity of therapeutic inadequacy. The question that follows the presence of a therapy is the question as to how to best use it.


Read Article

Rheumatology Roundup - ACR 2023

Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.

Read Article
APTURA 1 study of tocilizumab biosimilar. Not surprisingly no difference. I'm excited about this product. Hopefully be the end to our tocilizumab supply issues and significant societal savings Abstr#0445 #ACR23 @RheumNow
Richard Conway ( View Tweet )